Beihai Gofar Chuanshan Biological Co Ltd
600538
Company Profile
Business description
Beihai Gofar Chuanshan Biological Co Ltd main business include pharmaceutical manufacturing and pharmaceutical distribution industry, judicial IVD (in vitro diagnostic) technology services, molecular medical imaging centers and tumor radiotherapy centers and tumor telemedicine technology services, etc.
Contact
No. 3, Beibuwan Middle Road
Guangxi Zhuang Autonomous Region
BeihaiGuangxi536000
CHNT: +86 7793200619
Sector
Basic Materials
Stock type
Cyclical
Industry
Agricultural Inputs
Fiscal Year End
31 December 2025
Employees
453
Stocks News & Analysis
stocks
Potentially catastrophic ruling for ASX company
We raise our risk and uncertainty rating to reflect the impact of the ruling.
stocks
4 charts on Nvidia’s record $4 trillion market cap
Shares of the semiconductor giant have rocketed 280% over the past two years amid the AI boom.
stocks
Could merger breathe new life into struggling ASX asset manager?
Platinum’s board voted unanimously in favour of a merger we expect would be value accretive.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,815.30 | 5.00 | -0.06% |
| CAC 40 | 7,808.17 | 21.12 | -0.27% |
| DAX 40 | 24,160.64 | 94.67 | -0.39% |
| Dow JONES (US) | 44,438.78 | 67.27 | 0.15% |
| FTSE 100 | 8,998.06 | 56.94 | 0.64% |
| HKSE | 24,203.32 | 63.75 | 0.26% |
| NASDAQ | 20,655.59 | 70.06 | 0.34% |
| Nikkei 225 | 39,459.62 | 110.06 | -0.28% |
| NZX 50 Index | 12,678.69 | 7.99 | -0.06% |
| S&P 500 | 6,271.38 | 11.63 | 0.19% |
| S&P/ASX 200 | 8,570.40 | 9.70 | -0.11% |
| SSE Composite Index | 3,519.65 | 9.47 | 0.27% |